Identification of TMB, CD8 T-cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit-toxicity ratio of anti-PD-1/PD-L1 therapy.
Junyu LongXu YangJin BianDongxu WangAnqiang WangYu LinMingjun ZhengHaohai ZhangXin-Ting SangHaitao ZhaoPublished in: Clinical and translational medicine (2022)